RAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

RAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

Sep 13, 2008
Source URL: https://prod1.novartis.com/us-en/news/media-releases/rad001-combined-sandostatin-lar-depot-and-monotherapy-controls-growth-rare-pancreatic-neuroendocrine-tumors-0

List of links present in page
  1. https://prod1.novartis.com/us-en/us-en/news/media-releases/rad001-combined-sandostatin-lar-depot-and-monotherapy-controls-growth-rare-pancreatic-neuroendocrine-tumors-0